← All trials
NCT04792021
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 9, 2021
- Primary completion
- Jun 30, 2021
- Completion date
- Nov 30, 2021
- First posted
- Mar 10, 2021
- Last posted
- Mar 10, 2021
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ain Shams UniversityLead sponsor
- Ain Shams UniversityReponsible party - principal investigator
- Ain Shams UniversityStudy chair
- Misr International UniversityOverall official - principal investigator
- Misr International UniversityStudy director
- Misr International UniversityCollaborator
- Cairo UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.